The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Zytiga was produced by Janssen.
Two generic medicines also received positive opinions from the CHMP: Abiraterone Mylan (abiraterone acetate), a generic of Janssen’s Zytiga, for the treatment of metastatic prostate cancer and Fingolimod Mylan (fingolimod),
activity may derive ‘clinical benefit’ from the Erleada/Zytiga combination treatment, according to Janssen. ... However, Janssen disclosed yesterday that the Erleada/Zytiga combination treatment did not demonstrate significant benefit over Zytiga
Androgen inhibitor Erleada (apalutamide) is Janssen’s follow-up to its older, blockbuster prostate cancer drug Zytiga (abiraterone acetate), which has now been hit by the loss of patent protection and
Nubeqa’s rivals in the prostate cancer market include J&J’s Erleada (apalutamide) – its follow-up to its Zytiga (abirterone) brand which is now threatened by generic competition – and
Androgen inhibitor Erleada (apalutamide) is J&J’s follow-up up to big-selling prostate cancer drug Zytiga (abiraterone acetate), which has been hit by the loss of patent protection and ... Xtandi is now the dominant player in the market by value, with
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...